Recently medicinal cannabis has been at the forefront of media attention in the...
- Deals and M&As this week: CRISPR, Integral Molecular, Evotec
- Deals this week: Zealand Pharma, Fulcrum Therapeutics, Forendo Pharma
- M&As this week: Telix Pharmaceuticals, PCI Pharma, DZS Clinical Services
- Deals this week: Biohaven Therapeutics, POXEL, Ossianix
- Deals this week: Affimed, LEO Pharma, Harbour BioMed
Deals and M&As this week: CRISPR, Integral Molecular, Evotec
CRISPR Therapeutics and ViaCyte have formed a strategic collaboration to develop gene-edited, stem cell-derived therapies for diabetes patients.
Cablivi (caplacizumab) for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
Cablivi (caplacizumab) is a bivalent anti-Von Willebrand factor (vWF) nanobody indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP).
Will the UK relax its current regulations for cannabis-based products?
Recently medicinal cannabis has been at the forefront of media attention in the UK, and in July 2018 the UK home secretary announced that specialist doctors can legally prescribe cannabis-based products in the event of an exceptional clinical need.
Deals this week: Zealand Pharma, Fulcrum Therapeutics, Forendo Pharma
Zealand Pharma has sold its future royalty streams and potential commercial milestones for Soliqua® 100/33/Suliqua® and Lyxumia®/Adlyxin® to Royalty Pharma for $205m.
M&As this week: Telix Pharmaceuticals, PCI Pharma, DZS Clinical Services
Telix Pharmaceuticals Limited has acquired Atlab Pharma SAS for $10m.
The UK is home to the world leader in plant-derived cannabinoid therapeutics
The UK is the leading exporter of legal cannabis for medical usage, responsible for 67.7% of the global production of medical cannabis.
Why are novel therapies for glioblastoma patients not gaining approvals?
Despite the abundance of approvals and launches of novel therapies in the oncology space, glioblastoma multiforme (GBM), a solid tumor type, has had no new drugs to market since the approval of Genentech’s Avastin (bevacizumab) in 2009.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.